Following to the previous information on Dec. 9th. in 2024, we are excited to share our latest development status. Regarding the Phase I/II clinical trial of DFP-10917 in combination with ...

Try Now>> See the top stocks recommended by analysts >> Read More on PHAT: Phathom Pharmaceuticals NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Medicus Pharma (MDCX) announces a positively trending interim analysis for SKNJCT-003 Phase 2 clinical study to non-invasively treat basal cell carcinoma of the skin. The SKNJCT-003 clinical study ...

The Big Pharma company (NYSE: BMY) — the maker of the cancer immunotherapies Opdivo and Yervoy, the blood thinner Eliquis and the heart drug Camzyos, which it picked up in a $13.1 billion 2020 ...

New Delhi: Cancer patients facing prohibitive treatment costs in India can hope for relief: the nation's top drugmakers have started manufacturing key medicines for such diseases in the country.

“When you really start to dig deeper and see where the proliferation is coming from, you start to notice that it’s on the pollution of the pharmaceutical factories,” she explains.

What’s the base and worst case scenarios in the event of the tariff hike on pharmaceuticals by the US? (Image Credits: Pixabay) While US President Donald Trump announced the likely imposition of ...

The U.S. and its major trading partners have agreed to reciprocal tariff elimination for pharmaceutical products and chemicals used in drug production for the past 30 years, according to the U.S ...

Feb. 26 (UPI) --Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the United States and make the nation the world's leader in ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales up 66% to $103.3m. Despite a net loss of $466m in 2024, Madrigal's cash ...

However, I think aggressive growth investors might want to consider buying Madrigal Pharmaceuticals' shares. Some analysts project that Rezdiffra could generate peak annual sales of close to $3.5 ...